ライフサイエンスコーパス: survival was @2 months

1 Minimum follow-up for survival was 24.2 months.

2 a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 months; TC, 5.6 months), a

3 nths) in 6 trials with data available, and progression-free survival was 12.4 months (95% CI, 10.0-14.3 months) in 9 tria

4 (interquartile range, 2.3-3.75 years), the median ADT-free survival was 13 months (80% CI, 12 to 17 months) for the surv

5 The overall median progression-free survival was 13.2 months (95% CI 10.3-15.5), with a 12 month

6 Median progression-free survival was 13.3 months (95% CI 9.9-19.7) in the placebo gro

7 Median progression-free survival was 13.7 months (95% CI, 9.6-17.7).

8 Median hematologic progression-free survival was 14.8 months; 1-year progression-free and overall

9 The median progression-free survival was 17.5 months (95% CI, 8.6-25.0 months) and the me

10 edian follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated

11 Median progression-free survival was 2.1 months, and median overall survival was 8 mo

12 Median progression-free survival was 2.7 months (2.1 to 4.2).

13 Locally assessed progression-free survival was 2.7 months longer in the combination group than

14 Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib g

15 Median duration of follow-up for progression-free survival was 22.1 months (95% CI 20.3-23.9).

16 io, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (haza

17 Median progression-free survival was 3.48 months (95% CI 1.51-5.09) in the placebo gr

18 Median progression-free survival was 3.9 months (interquartile range [IQR], 1.5-5.9)

19 The median progression-free survival was 3.9 months for Ona + Bev versus 2.9 months for P

20 Median dysphagia progression-free survival was 4.1 months (95% CI 3.5-4.8) versus 3.4 months (3

21 Median progression-free survival was 4.6 months (95% CI 3.5-5.3) in the buparlisib gr

22 Median ITT progression-free survival was 5.2 months (95% CI, 3.2 to 7.1 months) and media

23 48 patients with PTEN-low tumours, median progression-free survival was 6.2 months (95% CI 3.6-9.1) with ipatasertib ver

24 pathway-activated patients (n=372), median progression-free survival was 6.8 months (95% CI 4.9-7.1) in the buparlisib gr

25 nts with known PI3K status (n=851), median progression-free survival was 6.8 months (95% CI 5.0-7.0) in the buparlisib gr

26 t a minimum follow-up of 18 months, median progression-free survival was 8.4 months for patients who discontinued treatme

27 Overall median progression-free survival was 8.5 months.

28 Median composite progression-free survival was 9.1 months (95% CI, 4.9 to 11.7 months); median

29 atio of 0.63 (95% CI 0.50-0.79; one-sided p<0.0001); median survival was 10.6 months (95% CI 9.1-12.1) for regorafenib ve

30 re 303 control arm deaths (83% prostate cancer), and median survival was 66 months.

31 For the entire study cohort, median overall survival was 11.1 months (95% CI, 4.1-27.2 months) from the f

32 d with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95% CI 11.8-15.7] vs 9.6 months [8.

33 Median overall survival was 15.7 months (95% CI 11.6-17.8) for ipilimumab 10

34 umab (n=241) compared with docetaxel (n=222; median overall survival was 15.7 months [95% CI 12.6-18.0] with atezolizumab

35 ion was 11 months (95% CI, 9-13 months), and median overall survival was 18 months (95% CI, 9-27 months).

36 4 patients (19.3%) who attained complete remission, overall survival was 19.7 months.

37 e in overall survival for patients with MRD: median overall survival was 20.1 months (95% CI 18.5-22.1) in the rindopepim

38 Median overall survival was 22.9 months (95% CI, 16.5 to upper level not ach

39 onths (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached; TC, 14.7 months).

40 7.5 months (95% CI, 8.6-25.0 months) and the median overall survival was 25.8 months (95% CI, 15.7-25.8 months).

41 a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% CI 24-34) in the twice-daily grou

42 The median overall survival was 30.0 months in the cetuximab-chemotherapy group

43 Median pooled overall survival was 30.2 months (95% CI, 26.5-33.7 months) in 6 tria

44 The median overall survival was 31.3 months (95% CI, 18.9-upper level not achiev

45 iotherapy groups, respectively (p=0.58), and median overall survival was 6.9 months (95% CI 5.1-8.3) versus 6.7 months (4

46 Median follow-up for overall survival was 7.00 months (IQR 2.96-8.77).

47 rogression-free survival was 2.1 months, and median overall survival was 8 months.

48 Median overall survival was 8.7 months (IQR, 3.6-16.8) with selumetinib + do

49 Median overall survival was 8.8 months (95% CI 7.7-10.2) in the rilotumumab

50 The median overall survival was 8.8 months for Ona + Bev and 12.6 months for Pla

51 Median cancer-related survival was 37.7 months (confidence interval 29-46 mo).